TECHBio-Techne

$72.47+37% 1Y

$72.47

$43.2252 weeks$72.62

TECH in its own filings

TECH's filing record carries one kind of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.

382

Events found in the filings · across 1,263 filings · the record starts in 1995

Hard flags: 1
Hard flags
Most recent filing: Sep 23, 2026
Most recent filing · Form 8-K
Record starts: May 10, 1995
Record starts · the earliest filing Ryufin holds for this name

Details›

Next results filingsame week as a year ago: expected around Nov 4, 2026
Late periodic report2 occurrences: 2017-08-29
SEC comment-letter activity32 occurrences: 2023-02-16

SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.

What the company said

The company's own words from its current reports to the SEC, newest first

Sep 23, 2026On September 23, 2026, Bio-Techne Corporation, a Minnesota corporation (“Bio-Techne”), held a special meeting of shareholders (the “Special Meeting”) to consider and vote on certain proposals related to the Agreement and Plan of Merger, dated as of June 25, 2026 (as it may be amended from time to time in accordance …Shareholder vote results · Form 8-K
Sep 14, 2026As previously disclosed, on June 25, 2026, Bio-Techne Corporation, a Minnesota corporation (“Bio-Techne”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Merck KGaA, Darmstadt, Germany, a German corporation with general partners (“Merck KGaA, Darmstadt, Germany”) and EMD Holdings NewCo …Other event · Form 8-K
Aug 12, 2026Bio-Techne Releases Fourth Quarter Fiscal 2026 Results.Earnings release · press release
Jun 26, 2026On June 25, 2026, Bio-Techne Corporation, a Minnesota corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Merck KGaA, Darmstadt, Germany, a German corporation with general partners (“Parent”), and EMD Holdings NewCo, Inc., a Minnesota corporation and a wholly-owned …Material agreement entered · Form 8-K
Jun 25, 2026Strengthening Leadership Position in Fast-Growing Life Sciences Markets.Regulation FD disclosure · press release
May 6, 2026Bio-Techne Releases Third Quarter Fiscal 2026 Results.Earnings release · press release
Feb 11, 2026Officer Transition On February 11, 2026, Bio-Techne Corporation (the “Company”) announced that Dr. Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment, will be transitioning from his role, effective March 1, 2026, and will remain with Bio-Techne for a period of time to support a smooth …Director or officer change · Form 8-K
Feb 4, 2026Bio-Techne Releases Second Quarter Fiscal 2026 Results.Earnings release · press release
Nov 5, 2025A quorum was present at the Annual Meeting with 140,827,559 shares represented personally or by proxy, which represents approximately 90.45% of the outstanding shares of the Company's common stock.Earnings release · Form 8-K